Chi Advisors LLC Freeline Therapeutics Holdings PLC Transaction History

Chi Advisors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	SELL	$0.42 - $0.63 $35,700 - $53,550	-85,000 Reduced 1.77%	4,729,419 $2.18 Million
Q3 2022 Nov 09, 2022	SELL	$0.69 - $1.1 $33,051 - $52,690	-47,900 Reduced 0.99%	4,814,419 $3.37 Million
Q1 2022 May 16, 2022	BUY	$0.92 - $2.03 $2.75 Million - $6.06 Million	2,985,930 Added 159.13%	4,862,319 $5.45 Million
Q4 2021 Feb 11, 2022	BUY	$1.97 - $3.45 $884,348 - $1.55 Million	448,908 Added 31.45%	1,876,389 $3.72 Million
Q3 2021 Nov 15, 2021	BUY	$3.04 - $8.9 $144,819 - $423,978	47,638 Added 3.45%	1,427,481 $4.87 Million
Q2 2021 Aug 11, 2021	SELL	$8.15 - $13.9 $39,935 - $68,110	-4,900 Reduced 0.35%	1,379,843 $11.2 Million
Q1 2021 May 14, 2021	BUY	$12.3 - $18.2 $291,251 - $430,957	23,679 Added 1.74%	1,384,743 $17 Million
Q4 2020 Feb 12, 2021	BUY	$14.94 - $18.3 $548,298 - $671,610	36,700 Added 2.77%	1,361,064 $24.9 Million
Q3 2020 Nov 12, 2020	BUY	$15.45 - $18.12 $20.5 Million - $24 Million	1,324,364 New	1,324,364 $20.7 Million

30.1K

Ticker FRLN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,972,300
Description
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in P...

Get notified when there are updates to the investment portfolio of Chi Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Chi Advisors LLC with notifications on news.